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cholesterol and the development of atherosclerosis. Rabbits, the 
classic model for the study of atherosclerosis, have an exceptional 
sensitivity even to low levels of dietary cholesterol, and they develop 
severe hypercholesterolemia th t is associated with the rapid 
development of atherosclerosis. 
Several characteristics of the rabbit are likely to be important in
its response to dietary cholesterol and contribute to its attraction as 
a transgenic model system. The rabbit is naturally deficient in 
hepatic lipase, an enzyme that is required for the catabolism of 
intermediate-density lipoproteins (IDL) and large high-density 
lipoproteins (HDL). Hepatic lipase is bound to vascular surfaces in 
the rabbit, and it is found at about 10% of the amount found in 
rodents, where most hepatic lipase circulates in plasma. Rabbit 
plasma has 30% to 50% less apoE than humans and about hreefold 
less than mice. Intravenous infusion ofapoE into rabbits has been 
shown to increase the clearance of ~- very low density lipoproteins 
(VLDL) in cholesterol-fed animals, as well as in the Watanabe 
heritable hyperiipidemic (WHHL) strain, a model for familial 
hypercholesterolemia. The rabbit has abundant levels ofcholesteryl 
ester transfer protein (CETP), which is absent in the mouse. The 
rabbit liver does not edit apoB mRNAin contrast to the mouse liver, 
where 85% of this mRNAis modified to the apoB48 form. We have 
taken advantage of these characteristics in generating our first 
group of transgenic rabbits. 
Hepatic lipase transgenic rabbits 
A liver-specific expression vector containing human hepatic 
lipase cDNA directed by regulatory components of the human 
apoE gene with the apoE hepatic control region was used to 
generate transgenic rabbits. Six independent lines of the New 
Zealand White strain were established that had germfine transmis- 
sion of the transgene. Hepatic lipase was detected in the plasma of 
these animals only after the administration f heparin. Enzymatic 
activity was found at levels ranging from sevenfold to 80-fold higher 
in transgenic rabbits than in nontransgenic littermates, correspond- 
ing approximately to integrated transgene copy number. This 
increase in hepatic lipase activity was associated with as much as a 
fivefold decrease inthe total plasma cholesterol levels and a twofold 
decrease in total plasma triglyceride l vels. 
Expression of the hepatic lipase transgene r sulted in dramatic 
reductions in the levels of large HDL1 and HDL2, as well as a 
reduction in the levels of small dense HDL3. The reduction in 
HDL accounted for as much as 75% of the overall decrease that was 
observed in plasma cholesterol. A significant reduction in the levels 
of IDL also was detected. These results demonstrated that hepatic 
lipase functions in the metabolism both of HDL and oflDL, and 
thereby plays an important role in plasma cholesterol homeostasis. 
Apolipoprotein E transgenic rabbits 
To investigate the mechanisms by which the level of apoE 
modulates plasma lipoprotein metabolism, transgenic rabbits were 
generated that overexpressed human apoE at -10 mg/dl  in plasma. 
Compared with nontransgenic l ttermates, transgenic rabbits had 
more than a twofold reduction in total plasma triglycerides and up 
to fivefold lower levels of VLDL. Transgenic d < 1.006 g/ml 
lipoproteins had an increased content ofapoE, and they were more 
effective than the corresponding nontransgenic lipoproteins in 
competing with low density lipoproteins (LDL) for receptor- 
binding on cultured fibroblasts. Labeled chylomicrons were re- 
moved more rapidly from the plasma by the liver in transgenic 
rabbits than in the normal control specimens. Results of negative- 
staining electron microscopy showed that large particles (>36 nm 
diameter) were absent from transgenic VLDL when compared with 
nontransgenic VLDL, where they accounted for 20% of this 
fraction. Thus in transgenic rabbits, large triglyceride-rich remnant 
lipoproteins have an enhanced rate of plasma clearance as a result of 
their greater affinity for cell-surface receptors as a result of the 
increased content of apoE on the remnants. 
In contrast, plasma cholesterol levels were unexpectedly in- 
creased up to twofold in transgenic rabbits due to an accumulation 
of circulating LDL and large apoE-rich HDLI. Transgenic LDL 
had the same binding affinity as control LDL for receptors on 
cultured fibroblasts, but intravenously injected human LDL were 
cleared more slowly in transgenic rabbits than in normal controls. 
However, a monoclonal ntibody to the rabbit LDL receptor was 
cleared at the same rate from the plasmas of both groups of rabbits 
indicating that they had similar eceptor levels. These observations 
suggest hat the increased levels of cholesteroPrich LDL (and 
HDL1) in transgenic rabbit plasma re the result of their reduced 
rate of clearance due to enhanced competition by high affinity 
apoE-rich chylomicron and VLDL remnants for hepatic lipopro- 
tein receptors. By directly determining the binding affinity of 
triglyceride-rich remnant lipoproteins for LDL receptors, apoE 
expression i directly modulates plasma LDL levels through com- 
petition of LDL with the remnants for the receptors. 
Apolipoprotein B transgenic rabbits 
An 80-kb human genomic DNA fragment spanning the 
human apoB gene was used to generate transgenic rabbits that 
expressed human apoB100. The concentration f human apoB in 
the plasma of the transgenic rabbits ranged between 5 and 100 
mg/dl. The high expressor t ansgenic rabbits had approximately 
threefold elevations in the plasma levels of triglycerides and 
cholesterol compared with nontransgenic controls. Approximately 
all of the cholesterol and human apoB in the plasma was in the LDL 
fraction. A striking feature of human apoB overexpression in rabbits 
is that it caused triglyceride enrichment ofthe LDL fraction. More 
than 75% of the triglycerides in the plasma of the human apoB 
transgenic rabbits were in this fraction• The triglyceride-enriched 
LDL were smaller and more dense than the native rabbit LDL and 
were characterized by markedly increased amounts of apoE and 
apoC-III. In nontransgenic control animals, most of the triglycer- 
ides were in the VLDI, and most of the apoE and apoC-III were in 
the VLDI and HDL fractions. In addition to increased LDL levels, 
overexpression f human apoB in rabbits resulted in lower plasma 
levels of HDL, cholesterol, and apoA-1. Because similar effects 
have been documented in transgenic mice that express human 
apoB, these findings suggests that triglyceride-rich LDL and 
lowered levels of HDL cholesterol may be hallmarks of apoB 
overexpression. 
Conclusion 
Transgenic technology has been applied to the rabbit to 
generate new animal models for the investigation of the functions 
of critical proteins in lipoprotein metabolism. These transgenic 
rabbits are new resources for the study of the mechanisms that 
regulate the response to dietary cholesterol and the development of 
atherosclerosis. 
John Taylor, PhD 
University of California at San Francisco 
San Francisco, Calif. 
THERAPY BASED ON GENE TRANSFER 
METHODS FOR LOCAL GENE DEL IVERY IN  
THE CARDIOVASCULAR SYSTEM 
The development of methods using the introduction of new 
genetic material for potential therapeutic applications in the car- 
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diovascular system is dependent on the evolution of two very 
distinct yet interdependent technologies: molecular vectors en- 
abling gene implantation i to target cells and "mechanical vectors" 
encompassing a variety of mechanisms and approaches for the 
delivery of vectors or vector-modified cells to anatomic regions of 
interest. The eventual practical application of gene transfer to the 
cardiovascular system will depend both on the choice of vectors that 
are capable of efficient gene transfer with an appropriate safety 
profile, as well as mechanical devices for the placement ofvectors in 
the region desired. 
In vivo vs. ex vivo approaches 
One approach to gene transfer uses the transduction fcells ex 
vivo, followed by their implantation i to an appropriate site for a 
f;mction. This implantation may use techniques as diverse as direct 
infusions, such as in the case of transfer of genetically modified bone 
marrow, and surgical implantation of matrices containing the 
genetically manipulated cells, such as in the implantation of 
biologic or synthetic vascular grafts incorporating transduced cells. 
Such approaches are particularly useful for the practical application 
of retroviral and liposomal/plasmid-based v ctors, given their 
comparatively low transduction efficiencies under most circum- 
stances. It has been a general observation that these transduction 
efficiencies (cells receiving the desired gene/total ceil target popu- 
lation) may be best optimized under carefully controlled condi- 
tions in vitro. One of the most significant reasons for this is the 
requirement for adequate periods of time for exposure of the 
target cell population to the transducing vectors; this requirement 
is most significant in the case of vectors which achieve relatively 
low maximum concentrations (e.g. retrovirus), or vectors mani- 
festing relatively low transduction efficiencies (most plasmid-based 
vectors). 
In vivo gent transfer, employing the direct placement of the 
molecular vector into the organism, isparticularly attractive in that 
it obviates the necessity of harvesting donor cells for transduction 
before implantation. Significant interest has accordingly been 
directed to the optimization of the variety of methods appropriate 
for in vivo gene transfer. In general, in vivo gene-transfer ap- 
proaches have been most productive in the context of adenoviral 
delivery, largely based on the relatively high concentrations which 
can routinely be achieved for purified adenoviral vector perfora- 
tions, as well as the ability of adenoviral vectors to effectively 
transduce nondividing cells. The latter consideration renders them 
most interesting for the applications involving cardiomyocytes or 
vascular cells with relatively low rates of turnover. 
Endovascular delivery 
The cardiovascular delivery of genetic vectors has used a wide 
range of methods. Several groups have dcmonstrated successful 
transduction ofvascular tissues by the isolation of arterial segments 
between dual ligatures or catheter balloons in conjunction with 
interruption ofall branch vessels from the selected segments; this is 
followed by the introduction ofvector suspensions into these target 
regions, and prolonged well time periods before reestablishment 
of blood flow. Such techniques have resulted in maximized fre- 
quencies of gene transfer as a consequence of the prolonged time 
available for binding of vector to the cells comprising the vascular 
wall. Unfortunately, these approaches may only be extrapolated to
the relatively infrequent clinical situations in which unbranched 
target segments may be occluded for prolonged periods. 
Conversely, experiments using porous balloon catheters to 
rapidly instill vector suspensions onto or into vessel walls from the 
luminal surface have been associated with transduction efficiencies 
significantly lower than values easily obtainable in vitro in ceil 
culture experiments. This is largely due to the kinetics governing 
the vector/cell attachment interaction, which are slow in compari- 
son with the bulk convection of the vector particles on exit from the 
catheter orifices. These experiments have also demonstrated the 
occurrence of prominent vectoremia fter instillation, the direct 
consequence of inefficient initialvector adsorption at the target site. 
Experiments are currently underway investigating approaches to 
maximize local disposition of vector while minimizing systemic 
distribution, by the use of adjunctive biocompatible matrices 
intended to maintain elevated pericellular concentration of the 
vector particles for extended time periods, thus favoring productive 
vector/cell collisions. Such matrices range from viscous hydrogels 
with or without the capability of intravascular polymerization to
stent-like solid devices for intravascular placement. Similarly, 
newer-generation delivery devices that are currently in develop- 
ment, as weli as in clinical use for delivery of traditional pharma- 
ceuticals, permit a degree of prolonged endovascular vector con- 
tact while maintaining distal blood flow and thus reducing the 
potential for ischemic sequelae. 
Per ivascu lar /myocard ia l  delivery 
Perivascular o  extravascular delivery has also used the surgical 
implantation of adjunctive biocompatible matrices intended to 
maintain elevated pericellular concentration f vector particles or 
incorporated cells. More recently, several devices with modified 
needles capable of direct injection into interstitial tissue of either 
myocardium or vasculature have been described. The provision for 
placement of vector particles within tissues appears to result in 
enhanced local transduction efficiency in comparison with that 
achievable by endoluminal delivery, presumably as a consequence 
of restriction of rapid vector redistribution by connective tissue. 
This confinement also results in the observation of comparatively 
limited systemic transduction after adenoviral delivery via intersti- 
tial injection. Recent experiments have demonstrated transduction 
of the adventitia nd perivascular tissue by transvascular needle 
injection using a delivery protocol requiting only several seconds. 
An alternative approach to perivascular delivery involves the 
instillation of vectors into the pericardiai space, for transduction of
epicardiai as well as parietal pericardial mesothelium. The inability 
of vectors to readily diffuse out of this space results in a sustained 
local vector concentration, leading to high frequency transduction 
of these fining cells. We have found this approach to be remarkably 
efficient and without evident ill effects in swine and dogs (n = 30), 
with expression of both intracetlular nd secreted proteins localized 
to the epicardium and pericardium. In addition to serving as a 
repository for prodrug (vector), we have hypothesized that the 
pericardial sac may serve as a secretory organ for transduced 
therapeutic proteins or their metabolites. Agents such as cytokines 
or growth factors may thus conceivably be delivered highly effi- 
ciently as well as locally to the epicardial tissue and vessels. 
Cur rent  cha l lenges  to  optimized vector delivery 
Key challenges concerning the eventual therapeutic applica- 
tion of gene transfer in the cardiovascular system using methods as 
outlined above include issues relating to delivery efficiency, true 
localization of delivered agent, and penetration of agent into the 
targeted tissues. These issues arise predominantly with relation to 
the physical properties of the vectors as well as the delivery 
processes under consideration. I creases in low delivery efficiencies 
are being addressed by attempts to prolong retention of vectors in 
the locale of target cells in order to permit enhanced attachment; 
these attempts include incorporation of vectors into a variety of 
matrices, as well as the use of extrahiminal sites of delivery in an 
effort to avoid competition of blood flow with vector binding and 
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localization. It is anticipated that use of such methods will also 
produce improvements in the degree of localization of delivery 
attainable. Finally, achievement of an even distribution of vector 
(prodrug) or gene product (drug) after the vector delivery remains 
a challenge to optimal local delivery. Improvements in this param- 
eter may result from ongoing work with agents to optimize vector 
permeation i to tissues, as well as from complementary mechanical 
approaches. 
Keith L. March, MD, PhD 
Indiana University 
Indianapolis, Ind. 
CELL-BASED TRANSFER 
ENDOTHEL IAL  CELLS  FOR SYSTEMIC  AND 
LOCAL GENE THERAPY 
Endothelial cells are excellent target cells for gene therapy and have 
played a prominent role in the development of techniques of 
somatic gene therapy for both vascular and nonvascular diseases. 1 
Endothelial cells regulate blood coagulation and fibrinolysis, vaso- 
motor tone, protein exchange between blood and tissues, anglo- 
genesis, and systemic mmune inflammatory esponses. Endothelial 
cells are also durable cells whose half-lives are measured inyears and 
thus are one of the longest-lived cells in the human body. Two 
additional characteristics make endothelial cells ideal target cells for 
somatic gene therapy. One characteristic is that endothelial cells are 
pluripotent, hat is, their phenotypic expression is regulated in part 
by their local environment. This enhances their capacity for 
successful transplantation to different locations within the circula- 
tory system. Second, endothelial cells are located at the blood- 
tissue interface and thus they provide aunique mechanism by which 
to deliver a recombinant protein to achieve an autoctine, paracrine, 
or endocrine ffect. 
Two basic strategies are used in somatic gene therapy. One is ex 
vivo gene therapy, in which specific target cells are harvested from 
the patienf, transduced ex vivo, and transplanted back into the 
patient. A variety of somatic ells have been examined for use in ex 
vivo gene therapy, including lymphocytes, endothefial cells, myo- 
cytes, fibroblasts, hematopoietic stern cells, and respiratory airway 
epithelial cells. The principle advantage of ex vivo gene therapy 
is that a population of pure, genetically modified target cells can 
be developed. In addition, none of the other tissues of the patient 
are exposed to any of the potentially harmful effects of the gene 
transfer technique. The major disadvantage is that this technique 
requires at least two procedures, one in which the target cells are 
harvested and undergo genetic modification, and a second pro- 
cedure to transplant the autologous, genetically modified cells 
back into the patient. 
A second form of somatic gene therapy is direct gene transfer 
in vivo, in which the transgene is transferred into the target cell in 
vivo. In this technique one can avoid the complications associated 
with the harvest as well as the transplantation cells back into the 
host. A major impediment to direct gene transfer is the availability 
of techniques of gene transfer that result in efficient and durable 
transgene expression i  vivo. 
In June 1989, two landmark studies were published that 
demonstrated that endothelial cells that underwent gene transfer ex 
vivo could be successfully transplanted into a vessel wall in vivo. In 
one study, Nabel and colleagues 2 uccessfully transplanted geneti- 
cally modified endothelial cells into the arterial wall of a pig. In this 
study, the transduced cells were shown to survive and express 
recombinant protein for as many as 4 weeks after transplantation. 
In a second study, Wilson and colleagues 3 transplanted genetically 
modified endothelial cells onto the surfaces of synthetic vascular 
grafts. The grafts seeded with transduced endothellum were 
subsequently placed as carotid interposition grafts into a canine 
model. This study established that genetically modified cells could 
be seeded successfully onto synthetic vascular grafts and that 
recombinant gene expression was confirmed in vivo. 
Because capillaries constitute more than 80% of the surface area 
of the circulatory system, they are a logical recipient site to 
transplant genetically modified endothelial cells in vivo. However, 
transplantation f transduced endothelial cells into the capillary 
bed is problematic. Although the endothelium of muscular arteries 
can be denuded and reseeded successfully, denudation of capillary 
endothelium as a means of facilitating cell transplantation might 
disrupt important normal microcirculatory hemodynamics and 
functions, as well as initiate an unwanted vessel wall injury response. 
Nonetheless, capillaries are a logical site for recombinant protein 
production to achieve either a regional or systemic therapeutic 
effect. 
We have targeted the capillary bed of skeletal muscle because it
possesses a high-density, accessible capillary network and is rela- 
tively resistant to ischemic injury. Furthermore, skeletal muscle, 
similar to the liver, is capable of regeneration after a variety of 
injuries. We first undertook a series of in vitro experiments o 
circumvent the need for denudation of capillary endothelium. We 
tested the hypothesis that activation of confluent endothelial cell 
monolayers in vitro by cytokines would promote adhesion and 
incorporation of endothefial cells seeded onto these monolayers. 
However, in the course of these experiments we identified a 
previously unrecognized capacity of endothelial cells to adhere and 
incorporate spontaneously into the untreated confluent endothelial 
cell monolayers in vitro. 4 In a second series of experiments, we 
documented that this property of spontaneous endothelial cell 
adhesion and incorporation i to preexisting monolayers can also 
occur in vivo and provide a strategy for somatic gene therapy. 4 
Transmission electron microscopy reveals that certain transduced 
endothelial cells were incorporated into the capillary wall, whereas 
others remained viable within the capillary lumen, forming multiple 
areas of local electron-dense communications with the underlying 
endothellum of the capillary wall. 
To promote greater incorporation of transduced endothefium, 
we evaluated two different strategies to induce angiogenesis in the 
capillary bed of skeletal muscle. The myotoxic anesthetic lidocaine 
promotes rapid degeneration of skeletal muscle sarcoplasm, fol- 
lowed by satellite cell activation and regeneration of the muscle 
fiber. A second approach to the induction of angiogenesis is to 
administer an agent that only induces angiogenesis. One such 
example is basic fibroblast growth factor. We characterized the 
angiogenic potential of  these agents in the tibialls anterior muscle 
of Sprague-Dawley rats. At all timepoints after injection, lidocalne 
treatment evoked asubstantially higher proliferative response than 
basic fibroblast growth factor, and more importantly the anglo- 
genie response was durable. Using this model oflidocaine-induced 
muscle regeneration and angiogenesis, we documented enhanced 
adhesion and incorporation of transduced endothelium into the 
capillary wall. 
Considerable progress has been made in the development of
experimental models of direct gene transfer to the arterial wall in 
vivo. The impetus for this work has been due to the recognition of 
the complexi W of ex vivo gene transfer and subsequent reimplan- 
tation of the transduced cells, as well as to advances in techniques 
of gene transfer. We have modified our animal model to achieve 
vascular isolation of the hind limb. In this regard, we have evaluated 
